Monitoring Effusion Recurrence and Management in Dogs and Cats

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Monitoring effusion recurrence necessitates a multi-modal approach integrating physical examination findings (e.g., respiratory effort, body weight trends), serial imaging (point-of-care ultrasound, thoracic radiographs), and laboratory trending (packed cell volume, total solids, effusion cytology). A body weight gain of 3-5% over 48 hours is a practical trigger for imaging, while loss of lung sliding on ultrasound indicates urgent need for intervention.
• The pathophysiology of effusion recurrence dictates monitoring intensity; transudative effusions (e.g., from hypoalbuminemia) reaccumulate slowly, whereas exudative effusions (from neoplasia or inflammation) recur rapidly due to increased vascular permeability or lymphatic obstruction. Neoplastic effusions require comprehensive cavity surveillance, not just focus on the primary tumor site.
• Recheck intervals are dictated by effusion aetiology and recurrence rate, ranging from 48-72 hours for exudative effusions to 7-14 days for transudative effusions. Patients with known neoplasia and rapid recurrence warrant shorter intervals, often every 3-7 days initially.
• Serial fluid analysis is critical for detecting complications, with gross appearance, total protein, nucleated cell count, and cytology serving as key parameters. A shift from transudate to exudate or the presence of intracellular bacteria warrants immediate re-evaluation, potentially including culture and susceptibility testing.
• Species-specific differences in effusion tolerance and clinical presentation are crucial; cats may mask respiratory compromise with lethargy, while dogs tolerate larger volumes before showing signs, necessitating scheduled imaging in the latter.
• Indwelling drains and ports require diligent monitoring for occlusion, infection, or tissue trauma, with daily assessment of fluid character, volume, exit site appearance, and patient comfort. Drain occlusion is indicated by declining output despite persistent effusion on imaging.

Body cavity effusions are dynamic clinical problems. After initial drainage, the central question shifts from diagnosis to trajectory: is fluid reaccumulating, at what rate, and does that rate demand intervention? This article provides a structured framework for monitoring pleural, peritoneal, and pericardial effusion recurrence in dogs and cats, with emphasis on clinical examination findings, serial imaging, laboratory trending, and decision thresholds that guide repeat drainage or escalation of therapy. It is written for practicing veterinarians managing patients across the recheck interval, from the immediate post-drainage period through long-term surveillance.

The procedural focus here assumes the initial diagnostic tap has been performed and characterized. Monitoring therefore relies on integrating physical examination, point-of-care ultrasound, thoracic radiographs, and serial laboratory values to detect recurrence before respiratory or hemodynamic compromise develops. The article also addresses how underlying aetiologies, particularly neoplasia and inflammatory processes, shape the frequency and intensity of monitoring. Where the evidence base is limited to case reports or retrospective series, that limitation is stated directly.

At a Glance

Pathophysiology of Effusion Recurrence

Effusion recurrence reflects ongoing imbalance between fluid production and resorption across a mesothelial surface. The mechanisms differ by body cavity and underlying disease. Transudative effusions, typically from hypoalbuminaemia or increased hydrostatic pressure, reaccumulate slowly and predictably. Exudative effusions from inflammation or neoplasia recur faster because the driving forces include increased vascular permeability, lymphatic obstruction, or active secretion by neoplastic cells.

The mesothelium itself is not passive. Mesothelial cells produce surfactant-like phospholipids that reduce friction, and they participate in fluid and solute transport. When inflamed or neoplastically transformed, these cells can shift fluid dynamics substantially. Fibrinous adhesions, seen commonly in pyothorax, create loculated pockets that complicate both detection and drainage. A retrospective series of dogs undergoing surgery for pyothorax found fibrinous adhesions in 12 of 15 dogs that developed postoperative complications, and diffuse pleural inflammation in 13 of 15, illustrating how the inflammatory milieu perpetuates fluid production even after source control.

Neoplastic effusions present a particular monitoring challenge. Tumor cells can shed into the cavity, seed the mesothelium, and establish independent fluid-producing foci. The case of a cat with mesenteric haemangiosarcoma illustrates this pattern: after debulking and adjuvant doxorubicin, the primary tumor remained absent on serial abdominal ultrasound, yet the cat eventually developed peritoneal effusion with suspected metastatic lymphadenopathy and hepatic metastasis. Monitoring therefore cannot focus solely on the primary site, it must survey the entire cavity and regional lymph nodes.

Monitoring Intervals and Visit Structure

The appropriate recheck interval depends on the rate of initial reaccumulation and the suspected aetiology. For patients discharged after therapeutic drainage, a recheck at 48 to 72 hours is reasonable for exudative effusions, while transudative effusions may be rechecked at 7 to 14 days. Patients with known neoplasia and prior rapid recurrence warrant shorter intervals, often every 3 to 7 days initially.

Each recheck visit should follow a consistent structure. Begin with owner-reported parameters: appetite, activity, respiratory rate at rest, and any coughing or abdominal distension. Then perform a targeted physical examination, including thoracic auscultation, abdominal palpation, and assessment of mucous membrane color and perfusion. Weigh the patient on the same scale at each visit. A gain of 3% to 5% of body weight over 48 hours is a practical trigger for imaging, though this threshold is a clinical heuristic instead of a validated standard.

Point-of-care ultrasound should be performed at every recheck when available. It detects smaller volumes than radiography, distinguishes free fluid from loculated pockets, and allows simultaneous assessment of lung sliding, cardiac motion, and organ parenchyma. Thoracic radiographs remain useful for evaluating pulmonary parenchyma and mediastinal structures, but they are less sensitive for small fluid volumes and require more time and radiation exposure. The choice between modalities should reflect the clinical question: ultrasound for fluid quantification and guidance, radiography for structural evaluation.

Laboratory Monitoring in the Recheck Period

Serial laboratory testing serves three purposes in effusion monitoring: detecting complications of drainage, tracking the underlying disease, and identifying shifts in effusion character. A minimum database at each recheck should include packed cell volume, total solids, and a biochemistry panel when the aetiology is metabolic or neoplastic. Trends matter more than single values. A falling packed cell volume with stable total solids suggests ongoing blood loss, while parallel declines suggest dilution from fluid shifts or reduced production.

Effusion analysis should be repeated when the clinical picture changes. A transudate that becomes exudative signals new inflammation or infection. A previously acellular fluid that develops a significant cell population warrants cytology and possibly culture. The American Society for Veterinary Clinical Pathology quality assurance guidelines provide a framework for ensuring that laboratory results, including cytology and fluid analysis, are reliable and interpretable across serial samples.

For patients on chemotherapy, hematologic monitoring follows the chemotherapeutic protocol instead of the effusion timeline. The cat with mesenteric haemangiosarcoma received doxorubicin at standard intervals, and its abdominal ultrasound was timed before the third dose to assess response. This coordination of imaging with treatment cycles allows simultaneous assessment of tumor response and effusion status without doubling visit frequency.

Species Differences in Monitoring Approach

Cats and dogs differ in their tolerance of effusion and in the physical examination findings that signal recurrence. Cats are more likely to mask respiratory compromise and may present with lethargy or anorexia instead of overt dyspnoea. They also develop pleural effusion from a narrower range of causes, with heart failure, neoplasia, and pyothorax predominating. Feline peritoneal effusions from neoplasia carry a grave prognosis, and monitoring should include explicit discussion of quality-of-life endpoints.

Dogs tolerate larger effusion volumes before clinical signs appear, particularly in the abdomen. A dog may accumulate several liters of peritoneal fluid before abdominal distension becomes obvious. This tolerance argues for scheduled imaging instead of reliance on physical examination alone. The MSD Veterinary Manual provides species-specific reference values for fluid analysis and clinical pathology that should inform interpretation of serial samples.

Long-Term Surveillance and Endpoint Planning

For effusions that recur despite medical management, long-term surveillance requires a defined plan. This plan should specify the monitoring interval, the imaging modality, the laboratory tests, and the criteria for escalating therapy or transitioning to palliative intent. The dog with pericardial mesothelioma managed without chemotherapy survived 21 months with a thoracic port and regular monitoring, demonstrating that structured surveillance can support prolonged survival even without definitive therapy. That case is a single report, but it illustrates the principle that monitoring frequency and intensity should match the clinical trajectory instead of a fixed protocol.

Endpoint planning should begin early, particularly for neoplastic effusions. Define what deterioration looks like: increasing drainage frequency, declining body condition, loss of appetite, or uncontrolled pain. Revisit these endpoints at each recheck, and document owner preferences for escalation versus comfort-focused care. This documentation supports consistent decision-making across clinicians and shift changes, and it respects the owner's role in the monitoring partnership.

Serial Fluid Analysis: Parameters That Change Management

Repeated thoracocentesis or abdominocentesis serves two distinct purposes: confirming that the effusion has the same character as before, and detecting a shift that signals a new complication. Every recheck tap should include gross inspection, total protein, nucleated cell count, and cytology. These four parameters separate a stable, uncomplicated recurrence from a deteriorating process.

Gross appearance is the first filter. A fluid that was previously serosanguineous and now appears milky, frankly hemorrhagic, or purulent demands immediate cytologic evaluation. A change from clear to turbid suggests increased cellularity or lipid content. The clinician should record color, turbidity, and whether the fluid clots, since clotting indicates recent hemorrhage or high fibrinogen content.

Total protein and nucleated cell count provide objective trend data. A modified transudate that progressively rises in protein toward exudate range signals increasing vascular permeability or inflammation. A septic exudate that remains septic on recheck, despite appropriate antimicrobial therapy, raises the question of a nidus such as a foreign body or abscess. Cytology should specifically assess for degenerate neutrophils, intracellular bacteria, neoplastic cells, and the presence of fibrin strands or mesothelial cell reactivity.

The decision to submit fluid for culture should be made on cytologic grounds. If intracellular bacteria are seen, aerobic and anaerobic culture with susceptibility testing is indicated. If the fluid is non-septic but the patient is systemically unwell, repeat culture may still be warranted because prior antimicrobial therapy can suppress bacterial growth while clinical infection persists. Post-operative complications after surgical management of pyothorax included persistent or recurrent pleural effusion as a recognized complication, and serial fluid character helped distinguish simple recurrence from ongoing infection or tissue necrosis.

Glucose and pH measurement in pleural or peritoneal fluid can support a diagnosis of septic effusion when cytology is equivocal. A fluid glucose more than 20 mg/dL below serum glucose, or an absolute fluid glucose below 40 mg/dL, supports bacterial consumption. These tests are inexpensive and can be run in-house. They are most useful when the cell count is borderline or when prior antibiotics have altered cell morphology.

Imaging Surveillance: What Each Modality Detects

Ultrasound is the primary imaging tool for monitoring effusion recurrence because it detects small volumes, guides drainage, and evaluates underlying structures. Serial abdominal ultrasound in a cat with mesenteric haemangiosarcoma demonstrated that the primary tumor remained absent while locoregional lymph nodes progressed and peritoneal effusion eventually developed, illustrating that imaging surveillance must track both the effusion and the disease process driving it. Use of doxorubicin chemotherapy following debulking surgery in a cat with mesenteric haemangiosarcoma documents this pattern of disease progression despite apparent local control.

Thoracic ultrasound can identify pleural fluid volumes too small to cause clinical signs, and it allows assessment of lung lobe consolidation, mediastinal masses, and pericardial thickening. In dogs recovering from pyothorax surgery, thoracic ultrasound can detect residual fluid pockets, pulmonary atelectasis, or persistent pleural thickening that might predispose to recurrence. Post-operative complications in dogs following surgical management of pyothorax reported that computed tomography demonstrated bilateral pleural effusion in the majority of affected dogs, suggesting that cross-sectional imaging may be more sensitive than ultrasound for detecting small-volume or loculated fluid.

Radiography retains a role when ultrasound is unavailable or when the patient is too unstable for positioning. A single lateral view can confirm the presence of significant effusion, but it cannot quantify small volumes or characterize fluid. Radiographs are also useful for evaluating the pulmonary parenchyma, cardiac silhouette, and mediastinum in patients with pleural effusion.

Computed tomography is reserved for specific indications: suspected foreign body, mass lesion requiring surgical planning, or unexplained recurrence despite adequate drainage. CT provides superior contrast resolution and three-dimensional localization, which is particularly valuable when surgical intervention is contemplated. The additional cost and anesthetic requirement limit its use to cases where the information will change management.

Decision Points in the Recheck Visit

The recheck examination should answer three questions. Is the effusion volume clinically significant? Has the fluid character changed? Is the underlying disease responding to therapy?

Effusion volume is assessed by a combination of physical examination, imaging, and the volume removed at drainage. A patient that requires drainage more frequently than every 7 to 10 days has rapidly recurring effusion and warrants escalation of therapy. A patient that remains comfortable for 3 to 4 weeks between drainages may be managed conservatively with continued monitoring.

Fluid character change is the most important trigger for re-evaluation of the diagnosis. A transudate that becomes an exudate, or a non-septic exudate that becomes septic, requires a new diagnostic plan. This may include repeat culture, advanced imaging, or biopsy. The clinician should not assume that the original diagnosis remains correct when the fluid phenotype changes.

Response of the underlying disease is assessed through serial imaging, laboratory parameters, and clinical signs. In the cat with mesenteric haemangiosarcoma, serial ultrasounds documented stable disease in locoregional lymph nodes while the primary tumor remained absent, and this stability supported continuation of chemotherapy. The same case report later documented progression to hepatic metastasis and peritoneal effusion, at which point the owner elected euthanasia. This sequence demonstrates that imaging surveillance directly informs both treatment continuation and endpoint planning.

Indwelling Drains and Ports: Monitoring the Device

When an indwelling thoracic or abdominal drain is placed, the monitoring protocol shifts. The drain itself becomes a potential source of infection, occlusion, or tissue trauma. Daily assessment should include the character and volume of fluid produced, the appearance of the exit site, and the patient's comfort.

A thoracic port placed for intermittent drainage requires less intensive daily monitoring but still needs regular assessment. Clinical course of canine pericardial mesothelioma managed without chemotherapy described a patient managed with a thoracic port for 21 months after subtotal pericardiectomy, with regular monitoring and symptomatic care supporting prolonged survival. The port allowed repeated drainage without repeated needle thoracocentesis, reducing patient stress and procedural risk.

Drain occlusion presents as declining output despite persistent effusion on imaging. Flushing protocols should follow the manufacturer's instructions and the clinician's judgment. Exit site infection is suggested by erythema, discharge, or pain, and requires cytology and culture of any exudate. The drain should be removed when output falls below a clinically insignificant volume for 24 to 48 hours, provided imaging confirms minimal residual fluid.

Documentation and Communication of Trends

Serial effusion monitoring generates data that must be recorded in a format that supports trend recognition. A simple flow sheet listing date, fluid volume removed, gross appearance, total protein, nucleated cell count, cytology summary, and imaging findings allows rapid comparison across visits. This documentation serves both clinical decision-making and client communication.

The owner should understand the monitoring plan before it begins. They need to know how often rechecks are scheduled, what each visit involves, and what signs should prompt an earlier visit. Tachypnoea, lethargy, anorexia, or abdominal distension are indications for immediate re-evaluation instead of waiting for the scheduled appointment.

When the underlying disease is progressive despite optimal management, the monitoring data provide an objective basis for discussing prognosis and endpoint planning. The transition from stable disease to progressive disease, documented through serial imaging and fluid analysis, supports a frank conversation about quality of life and humane options. The pericardial mesothelioma case demonstrates that prolonged survival is possible with aggressive effusion control, but it also illustrates that the underlying neoplastic process ultimately determines outcome.

Recognized Complications and Early Detection

Recurrence of effusion is itself the primary failure mode, but the complications that accompany repeated drainage and device placement carry their own morbidity. Seroma formation at drain exit sites, subcutaneous tracking of fluid around a malpositioned catheter, and occlusion of indwelling drains by fibrin or cellular debris are common mechanical failures. Each is detected by comparing the volume drained at each session against the expected yield, by palpating the surrounding tissues for subcutaneous fluid accumulation, and by observing the character of fluid flow through the tubing. A drain that was productive and becomes non-productive while the patient's respiratory effort or abdominal distension worsens should be assumed obstructed or displaced until proven otherwise, not presumed to reflect resolution of the effusion.

Pleural drainage carries the additional risks of pneumothorax, pulmonary laceration, and re-expansion pulmonary edema. In the post-operative period after surgical management of pyothorax, intra-operative complications such as iatrogenic lung injury and hypotension have been documented in nearly half of affected dogs in one retrospective series, and these events can set the stage for prolonged air leaks or delayed recovery that masquerade as effusion recurrence post-operative complications in dogs following surgical management of pyothorax. Serial thoracic ultrasound or radiography after each drainage event will identify a persistent pneumothorax that fails to resolve, and worsening respiratory signs with a dry tap should prompt imaging before repeat drainage is attempted.

Peritoneal effusion recurrence carries the risk of hypoalbuminaemia from repeated protein loss, particularly with chylous or exudative fluids, and of bacterial peritonitis introduced through repeated catheterization. Fever, progressive lethargy, or a change in fluid character from transudate to exudate with degenerate neutrophils should trigger cytological re-evaluation and culture. In cats with suspected neoplasia, the appearance of new effusion after a period of stability may represent metastatic progression instead of simple local recurrence, as illustrated by a case of mesenteric haemangiosarcoma in which peritoneal effusion appeared only after metastatic disease was documented ultrasonographically doxorubicin chemotherapy following debulking surgery in a cat with mesenteric haemangiosarcoma.

Common Errors and Corrective Actions

The most frequent error in monitoring is treating the fluid analysis as a static result instead of a trend. A single sample that appears less inflammatory than the previous one may reflect sampling site variation, dilution by recent lavage, or laboratory variability instead of true improvement. The corrective action is to standardize the sampling technique, record the volume and appearance at each tap, and compare serial results against the same laboratory's reference intervals, as recommended in ASVCP quality assurance and laboratory standards guidance.

A second error is delaying imaging until the patient is clinically decompensated. Effusions can reaccumulate to a volume that compromises ventilation or perfusion before the owner notices a change. Scheduled imaging at each recheck visit, even in the stable patient, detects recurrence earlier and allows smaller, less stressful drainage events. A third error is attributing every deterioration to the effusion itself. In patients with known neoplasia, progressive weight loss, anorexia, or organomegaly may signal metastatic disease even when the effusion volume is stable, and imaging of the primary site and regional lymph nodes should accompany fluid assessment.

Limitations of Current Evidence

The evidence base for effusion monitoring is composed largely of retrospective case series and single case reports. The prolonged survival of a dog with pericardial mesothelioma managed without chemotherapy, supported by regular monitoring and symptomatic care, demonstrates that individual outcomes can diverge substantially from published expectations, but it does not establish a general management standard clinical course and extended survival in a canine patient with pericardial mesothelioma. Expert opinion still differs on the optimal interval between recheck visits, the value of routine fluid analysis in the asymptomatic patient, and the threshold at which repeated drainage should be abandoned in favour of surgical intervention or euthanasia. These decisions should be made collaboratively with the owner, with explicit discussion of the uncertainty involved.

Referral, Consultation, and Reporting

Referral to a specialist is warranted when effusion recurrence accelerates despite appropriate management, when repeated drainage is required more frequently than every few days, when the underlying diagnosis remains unknown after initial evaluation, or when surgical options such as pericardiectomy, pleurodesis, or resection of a mass have not been explored. Consultation with a clinical pathologist is appropriate when fluid cytology is ambiguous, when cell counts are borderline between transudate and exudate, or when atypical cells raise the question of neoplasia without confirming it. Laboratory involvement may also be needed for specialised testing such as fluid triglyceride and cholesterol measurement in suspected chylous effusions, or immunocytochemistry on fluid samples.

Regulatory reporting obligations vary by jurisdiction and by the suspected cause of the effusion. Effusions associated with notifiable diseases, with food-producing animals, or with suspected foreign animal disease should be reported according to local requirements. The WOAH terrestrial animal health standards provide an international framework for disease surveillance and reporting, and the AVMA practice resources offer guidance on professional obligations in the United States. Practitioners should familiarise themselves with the requirements of their own regulatory body before a reportable condition is encountered.

Frequently Asked Questions

How Should I Adjust Monitoring Frequency When Financial Constraints Limit Recheck Visits?

Prioritize visits that yield actionable decisions. If weekly imaging is not feasible, combine serial physical examination with owner-reported respiratory effort or abdominal girth measurements at home. Reserve ultrasound for clinical deterioration or scheduled decision points, such as before a planned chemotherapy cycle. When laboratory testing is limited, run a minimum database of packed cell volume, total solids, and fluid analysis only if drainage is performed. The American Society for Veterinary Clinical Pathology quality assurance guidelines support using validated point-of-care methods when full laboratory panels are unavailable. Document the reduced monitoring plan and the rationale in the medical record so later clinicians understand why intervals were extended.

What Is the Minimum Equipment Set Needed to Monitor Effusion Recurrence Reliably?

A scale, stethoscope, and ultrasound unit with a curvilinear probe cover most recheck needs. Ultrasound permits subjective effusion volume estimation, cardiac assessment, and guided drainage when needed. If ultrasound is unavailable, serial body weight, thoracic auscultation for muffled heart sounds, and percussion of the abdomen provide crude but useful trend data. A refractometer for total solids and a microhematocrit centrifuge allow basic fluid characterization. For practices without in-house cytology, submit air-dried smears to a commercial laboratory. The MSD Veterinary Manual clinical resources describe physical examination findings that support effusion recurrence when imaging is not possible. Document the limitations of the examination technique used at each visit.

How Do I Monitor a Patient with a Chronic Indwelling Pleural Port Between Drains?

Palpate the port site for swelling, heat, or pain at each visit. Aspirate the port only when clinical signs suggest reaccumulation, not on a fixed schedule, to reduce infection risk. Record the volume and character of each drainage event. Compare drainage intervals over time, a progressive shortening of the interval between drains suggests disease progression or port dysfunction. If the port becomes difficult to aspirate, flush gently with sterile saline and assess for occlusion. The canine pericardial mesothelioma case managed with a thoracic port illustrates that long-term port use with regular monitoring can support stable quality of life for many months. Instruct owners to monitor for tachypnoea or lethargy and to seek recheck if these signs appear before the expected drain interval.

How Should I Communicate Recurrence Risk and Monitoring Plans to Owners in a Way That Supports Compliance?

Frame monitoring as a series of small decisions instead of a single prognosis. Explain that each recheck answers one question: is the effusion returning faster, slower, or at the same rate? Give owners a written schedule with the next visit date and a list of signs that warrant earlier contact. Use the trend in drainage intervals to show whether treatment is working. For example, if the interval between drains lengthens, state that the plan is working and continue. If it shortens, discuss next options before a crisis develops. The post-operative pyothorax case series demonstrates that complications can arise even after apparently successful surgical management, which supports preparing owners for the possibility of recurrence despite optimal initial treatment.

What Should I Do When Serial Imaging Shows Stable Effusion Volume but the Patient Is Clinically Worse?

Separate effusion volume from effusion effect. A stable volume can still cause clinical decline if the patient's cardiovascular or respiratory reserve has fallen, or if the fluid composition has changed. Perform a therapeutic drainage and reassess clinical status within 12 to 24 hours. If the patient improves after drainage, the effusion is contributing to signs and drainage frequency should increase. If the patient does not improve, pursue alternative causes such as primary respiratory disease, cardiac failure, or neoplasia. Analyze fluid from each drainage event for cell counts, total solids, and cytology, because a shift from transudate to exudate or the appearance of neoplastic cells changes management. The mesenteric hemangiosarcoma case shows that peritoneal effusion can appear late in disease progression while imaging findings remain otherwise stable.

How Do Monitoring Priorities Differ Between a First Recurrence and a Third or Later Recurrence?

The first recurrence is a diagnostic event. Confirm the fluid type, repeat cytology, and consider advanced imaging to identify why the initial treatment failed. The third recurrence is a management event. At that point, the diagnosis is usually established and the goal shifts to palliation and quality of life. Recheck intervals should shorten after each recurrence, and the threshold for surgical options such as pericardiectomy or pleurodesis should be discussed explicitly. The pericardial mesothelioma case demonstrates that surgical intervention after recurrent effusion can markedly extend survival without chemotherapy. For later recurrences, ask the owner about quality-of-life priorities at every visit and document the response, because the monitoring plan should adapt to the owner's stated goals.

Related Clinical & Scientific Guides

• Peripheral Blood Smear Evaluation: A Step-by-Step Guide
• Reticulocyte Counts in Veterinary Medicine: Clinical Utility and Interpretation
• Cerebrospinal Fluid Analysis in Veterinary Neurology: Collection and Interpretation

References and Further Reading

• Use of doxorubicin chemotherapy following debulking surgery in the treatment of a cat with mesenteric hemangiosarcoma.. 2022.
• Post-operative complications in 15 dogs following surgical management of pyothorax: a retrospective multi-institutional study.. 2026.
• Clinical Course and Extended Survival in a Canine Patient with Pericardial Mesothelioma Managed Without Chemotherapeutic Intervention. 2025.
• American Society for Veterinary Clinical Pathology Guidelines. American Society for Veterinary Clinical Pathology.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.
• American Veterinary Medical Association Practice Resources. American Veterinary Medical Association.
• WOAH Terrestrial Animal Health Code. WOAH.

Related Articles

• Monitoring Blood Glucose Curves in Diabetic Dogs and Cats
• Monitoring Hepatic Enzyme Trends in Dogs and Cats: Clinical Significance
• Leukogram Patterns in Dogs and Cats: A Diagnostic Guide
• Monitoring Cardiac Biomarkers in Heart Failure Management
• Monitoring Serum Bile Acids for Hepatobiliary Disease Management

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.